IL299924B2 - CFTR regulators and methods of using them - Google Patents

CFTR regulators and methods of using them

Info

Publication number
IL299924B2
IL299924B2 IL299924A IL29992423A IL299924B2 IL 299924 B2 IL299924 B2 IL 299924B2 IL 299924 A IL299924 A IL 299924A IL 29992423 A IL29992423 A IL 29992423A IL 299924 B2 IL299924 B2 IL 299924B2
Authority
IL
Israel
Prior art keywords
compound
och
hydrogen
ochch
halogen
Prior art date
Application number
IL299924A
Other languages
English (en)
Hebrew (he)
Other versions
IL299924B1 (en
IL299924A (en
Inventor
Alan Verkman
Marc H Levin
Onur Cil
Original Assignee
Univ California
Alan Verkman
Marc H Levin
Onur Cil
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California, Alan Verkman, Marc H Levin, Onur Cil filed Critical Univ California
Publication of IL299924A publication Critical patent/IL299924A/en
Publication of IL299924B1 publication Critical patent/IL299924B1/en
Publication of IL299924B2 publication Critical patent/IL299924B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/135—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Prostheses (AREA)
  • Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
IL299924A 2015-12-24 2016-12-23 CFTR regulators and methods of using them IL299924B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562387591P 2015-12-24 2015-12-24
PCT/US2016/068561 WO2017112947A1 (en) 2015-12-24 2016-12-23 Cftr regulators and methods of use thereof

Publications (3)

Publication Number Publication Date
IL299924A IL299924A (en) 2023-03-01
IL299924B1 IL299924B1 (en) 2024-09-01
IL299924B2 true IL299924B2 (en) 2025-01-01

Family

ID=59091233

Family Applications (2)

Application Number Title Priority Date Filing Date
IL299924A IL299924B2 (en) 2015-12-24 2016-12-23 CFTR regulators and methods of using them
IL260210A IL260210B2 (en) 2015-12-24 2018-06-21 cftr regulators and methods of using them

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL260210A IL260210B2 (en) 2015-12-24 2018-06-21 cftr regulators and methods of using them

Country Status (15)

Country Link
US (2) US20190031630A1 (pl)
EP (1) EP3394083B9 (pl)
JP (1) JP6894902B2 (pl)
KR (1) KR102723194B1 (pl)
CN (1) CN108699107B (pl)
AU (2) AU2016377782B2 (pl)
CL (1) CL2018001714A1 (pl)
CO (1) CO2018007239A2 (pl)
ES (1) ES2901002T3 (pl)
IL (2) IL299924B2 (pl)
PL (1) PL3394083T3 (pl)
PT (1) PT3394083T (pl)
RU (1) RU2742934C2 (pl)
WO (1) WO2017112947A1 (pl)
ZA (1) ZA201804228B (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3066112T3 (en) 2015-12-24 2026-05-11 The Regents Of The Univ Of California Cftr regulators and methods of use thereof
IT201700085714A1 (it) * 2017-07-26 2019-01-26 Luigi Maiuri Approccio terapeutico per il trattamento e/o prevenzione di condizioni di sensibilità al glutine.
EP3672598A4 (en) * 2017-08-24 2021-04-28 The Regents of The University of California OCULAR PHARMACEUTICAL COMPOSITIONS
FR3096890B1 (fr) * 2019-06-07 2021-05-14 H4 Orphan Pharma Utilisation d’une molécule opioïde pour traiter l’œil sec et l’œil allergique.
US20220071549A1 (en) * 2020-09-08 2022-03-10 The Regents Of The University Of California Apparatus, systems and methods of use for ocular surface potential difference measurement
PY2193067A (es) 2020-10-23 2022-06-20 Ildong Pharmaceutical Co Ltd Compuestos moduladores del cftr, composiciones y usos de estos
CN113527225B (zh) * 2021-07-15 2022-11-18 南昌大学 一种丙烯酰噻二唑衍生物及其制备方法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005075435A1 (en) * 2004-01-30 2005-08-18 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1917999A (en) 1998-03-31 1999-10-18 Warner-Lambert Company Quinoxalinones as serine protease inhibitors such as factor xa and thrombin
AP2005003292A0 (en) * 2002-09-30 2005-06-30 Univ California Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof
US7977322B2 (en) 2004-08-20 2011-07-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US20090105240A1 (en) * 2007-10-17 2009-04-23 Tomas Mustelin Methods for treating leukemia and myelodysplastic syndrome, and methods for identifying agents for treating same
AU2009221327B2 (en) 2008-03-05 2014-03-27 Merck Patent Gmbh Quinoxalinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes
US8314239B2 (en) 2008-10-23 2012-11-20 Vertex Pharmaceutical Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
WO2010073011A2 (en) * 2008-12-23 2010-07-01 Betagenon Ab Compounds useful as medicaments
TWI450891B (zh) * 2010-12-29 2014-09-01 Dev Center Biotechnology 新穎微管蛋白抑制劑
AU2015229188A1 (en) * 2014-03-13 2016-09-29 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing CFTR activity
EP3157917B1 (en) 2014-06-19 2020-03-18 Proteostasis Therapeutics, Inc. Compounds, compositions and methods of increasing cftr activity

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005075435A1 (en) * 2004-01-30 2005-08-18 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters

Also Published As

Publication number Publication date
RU2742934C2 (ru) 2021-02-11
ES2901002T3 (es) 2022-03-21
RU2018126959A (ru) 2020-01-24
PL3394083T3 (pl) 2022-01-17
PT3394083T (pt) 2021-12-07
CO2018007239A2 (es) 2018-07-19
JP6894902B2 (ja) 2021-06-30
NZ743720A (en) 2024-08-30
EP3394083B1 (en) 2021-09-01
CN108699107A (zh) 2018-10-23
CA3009531A1 (en) 2017-06-29
US20200140402A1 (en) 2020-05-07
WO2017112947A1 (en) 2017-06-29
AU2021257948A1 (en) 2021-11-25
CN108699107B (zh) 2022-05-10
AU2016377782B2 (en) 2021-07-29
KR20180101415A (ko) 2018-09-12
RU2018126959A3 (pl) 2020-08-20
CL2018001714A1 (es) 2018-10-26
IL260210A (en) 2018-07-31
AU2016377782A1 (en) 2018-07-12
ES2901002T9 (es) 2022-06-20
AU2021257948B2 (en) 2023-11-30
IL260210B2 (en) 2023-06-01
IL299924B1 (en) 2024-09-01
EP3394083B9 (en) 2022-04-27
IL299924A (en) 2023-03-01
EP3394083A4 (en) 2019-09-04
US20190031630A1 (en) 2019-01-31
BR112018012927A2 (en) 2018-12-11
ZA201804228B (en) 2020-09-30
EP3394083A1 (en) 2018-10-31
US11192869B2 (en) 2021-12-07
JP2018538354A (ja) 2018-12-27
KR102723194B1 (ko) 2024-10-28

Similar Documents

Publication Publication Date Title
IL299924B1 (en) Cftr regulators and methods of use thereof
WO2014144761A3 (en) Increasing specificity for rna-guided genome editing
WO2014152389A8 (en) Imaging agent for detection of diseased cells
WO2015183813A3 (en) Design, synthesis and characterization of metal organic frameworks
WO2016096174A8 (en) Cyclic dinucleotides for cytokine induction
TN2017000204A1 (en) Triazolopyrimidine compounds and uses thereof
PH12015501993A1 (en) Pyrazole-amide compound and medicinal uses therefor
UA116923C2 (uk) (6S,9aS)-N-БЕНЗИЛ-6-[(4-ГІДРОКСИФЕНІЛ)МЕТИЛ]-4,7-ДІОКСО-8-({6-[3-(ПІПЕРАЗИН-1-ІЛ)АЗЕТИДИН-1-ІЛ]ПІРИДИН-2-ІЛ}МЕТИЛ)-2-(ПРОП-2-ЕН-1-ІЛ)-ОКТАГІДРО-1H-ПІРАЗИНО[2,1-c][1,2,4]ТРИАЗИН-1-КАРБОКСАМІДНА СПОЛУКА
MX392829B (es) Analogos sinteticos de las ecteinascidinas y su uso como agentes antitumorales
JP2013543842A5 (pl)
PH12016502147A1 (en) Substituted 4-phenylpiperidines, their preparation and use
EA201690127A1 (ru) Состав на основе ингибиторов syk
WO2016176473A8 (en) Apelin receptor agonists and methods of use thereof
EA201391558A1 (ru) Тетрагидропиразоло[1,5-а]пиримидины как противотуберкулезные соединения
WO2017015433A3 (en) Compound targeting il-23a and b-cell activating factor (baff) and uses thereof
WO2014197093A3 (en) All water-based nanopatterning
WO2015000431A9 (zh) 替唑尼特氨基甲酸酯及其在药学中的应用
WO2018183089A8 (en) Compositions for treating and/or preventing cancer
PH12017502388A1 (en) 1,4-di-substituted imidazole derivative
WO2018035346A8 (en) KINASE INHIBITING COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING CANCER
MX2021004474A (es) Compuestos que contienen deuterio.
PH12015500733A1 (en) Method of weight management
AU2016351424A8 (en) Pyranodipyridine compound
WO2015024016A3 (en) 2-piperidinyl substituted n,3-dihydroxybutanamides
MX2020002505A (es) Compuestos heteroaromaticos sustituidos con cicloolefinas y su uso.